Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Résultat de la recherche
1 recherche sur le mot-clé 'nasal spray'
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
Beyond the hype and hope: Critical considerations for intranasal oxytocin research in autism spectrum disorder / Gail A. ALVARES in Autism Research, 10-1 (January 2017)
[article]
Titre : Beyond the hype and hope: Critical considerations for intranasal oxytocin research in autism spectrum disorder Type de document : Texte imprimé et/ou numérique Auteurs : Gail A. ALVARES, Auteur ; Daniel S. QUINTANA, Auteur ; Andrew J. O. WHITEHOUSE, Auteur Article en page(s) : p.25-41 Langues : Anglais (eng) Mots-clés : oxytocin neuropeptide hormones nasal spray Index. décimale : PER Périodiques Résumé : Extensive research efforts in the last decade have been expended into understanding whether intranasal oxytocin may be an effective therapeutic in treating social communication impairments in individuals with autism spectrum disorder (ASD). After much hyped early findings, subsequent clinical trials of longer-term administration have yielded more conservative and mixed evidence. However, it is still unclear at this stage whether these more disappointing findings reflect a true null effect or are mitigated by methodological differences masking true effects. In this review, we comprehensively evaluate the rationale for oxytocin as a therapeutic, evaluating evidence from randomized controlled trials, case reports, and open-label studies of oxytocin administration in individuals with ASD. The evidence to date, including reviews of preregistered trials, suggests a number of critical considerations for the design and interpretation of research in this area. These include considering the choice of ASD outcome measures, dosing and nasal spray device issues, and participant selection. Despite these limitations in the field to date, there remains significant potential for oxytocin to ameliorate aspects of the persistent and debilitating social impairments in individuals with ASD. Given the considerable media hype around new treatments for ASD, as well as the needs of eager families, there is an urgent need for researchers to prioritise considering such factors when conducting well-designed and controlled studies to further advance this field. En ligne : http://dx.doi.org/10.1002/aur.1692 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=302
in Autism Research > 10-1 (January 2017) . - p.25-41[article] Beyond the hype and hope: Critical considerations for intranasal oxytocin research in autism spectrum disorder [Texte imprimé et/ou numérique] / Gail A. ALVARES, Auteur ; Daniel S. QUINTANA, Auteur ; Andrew J. O. WHITEHOUSE, Auteur . - p.25-41.
Langues : Anglais (eng)
in Autism Research > 10-1 (January 2017) . - p.25-41
Mots-clés : oxytocin neuropeptide hormones nasal spray Index. décimale : PER Périodiques Résumé : Extensive research efforts in the last decade have been expended into understanding whether intranasal oxytocin may be an effective therapeutic in treating social communication impairments in individuals with autism spectrum disorder (ASD). After much hyped early findings, subsequent clinical trials of longer-term administration have yielded more conservative and mixed evidence. However, it is still unclear at this stage whether these more disappointing findings reflect a true null effect or are mitigated by methodological differences masking true effects. In this review, we comprehensively evaluate the rationale for oxytocin as a therapeutic, evaluating evidence from randomized controlled trials, case reports, and open-label studies of oxytocin administration in individuals with ASD. The evidence to date, including reviews of preregistered trials, suggests a number of critical considerations for the design and interpretation of research in this area. These include considering the choice of ASD outcome measures, dosing and nasal spray device issues, and participant selection. Despite these limitations in the field to date, there remains significant potential for oxytocin to ameliorate aspects of the persistent and debilitating social impairments in individuals with ASD. Given the considerable media hype around new treatments for ASD, as well as the needs of eager families, there is an urgent need for researchers to prioritise considering such factors when conducting well-designed and controlled studies to further advance this field. En ligne : http://dx.doi.org/10.1002/aur.1692 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=302